Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Brought to you by

Alnylam, Arrowhead swap IP

11 Oct 2016

Executive Summary

RNAi therapeutics developer Alnylam Pharmaceuticals Inc. has licensed nanomedicine firm Arrowhead Research Corp. rights to IP for use in the discovery, development, and commercialization of an RNAi therapeutic aimed at hepatitis B (HBV). At the same time, Arrowhead has licensed Alnylam rights to its Dynamic PolyConjugate (DPC) technology for use in developing an RNAi therapy for an undisclosed target in the Alnylam 5x15 program.
Deal Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • Drug Delivery
  • Biotechnology
    • Antisense, Oligonucleotides
    • Large Molecule
Deal Status
  • Final
Deal Type
  • Alliance
    • Intra-Biotech Deal
    • Product or Technology Swap
    • R&D and Marketing (Licensing)

Related Companies

UsernamePublicRestriction

Register

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By